GlassScriptPhysician profile
Danielle Renee Shaw
NPI 1093705915
$1,585.61
in general payments reported to CMS, 2019-2025
14 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $250 · 2022: $253 · 2023: $450 · 2024: $195 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $353.17 | 2020-2022 | |
| Tris Pharma INC | $154.43 | 2019-2023 | Quillivant, Dyanavel Xr, Quillichew Er |
| Silk Road Medical, INC. | $150.00 | 2022 | |
| Novo Nordisk INC | $125.00 | 2023 | Wegovy |
| Glaxosmithkline, LLC. | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $112.12 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $104.17 | 2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $98.11 | 2025 | |
| Abbvie INC. | $90.51 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $89.43 | 2023 | Breztri |
| Almatica Pharma LLC | $22.12 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Exact Sciences Corporation | $21.69 | 2023 | Cologuard Collection Kit |
| Sage Therapeutics, LLC | $14.86 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.